Table 1

Baseline demographic and clinical characteristics

ParameterAxial SpA (n=49)Peripheral SpA (n=16)
Age (years)35.7±11.537.8±14.3
Symptom duration (years)3.6 (0.2–44.8)1.3 (0.2–18.6)
Male gender25 (51.0)8 (50.0)
HLA-B27 (+)39 (79.6)7 (43.8)
Presence or history of arthritis8 (16.3)15 (93.8)
Presence or history of enthesitis*11 (22.4)4 (25.0)
Presence or history of uveitis10 (20.4)1 (6.3)
Presence or history of psoriasis4 (8.2)7 (43.8)
Family history of SpA21 (42.8)7 (43.8)
Treatment with NSAIDs44 (89.8)9 (56.3)
Treatment with DMARDs1 (2.0)10 (62.5)
Smoking, currently12 (24.5)3 (18.8)
CRP (mg/dl)0.7 (0.0–2.7)0.7 (0.0–10.3)
Active lesions on MRI SIJ33 (89.2)
BASDAI, numeric rating scale4.6 (0.4–9.6)
ASDAS2.7 (0.4–5.4)
BASMI2 (0–9)
  • In the case of numeric variables, results are given as mean±SD (normal distribution) or median and range (skewed distribution); dichotomous parameters are presented as frequencies with percentage.

  • *Past or present enthesitis diagnosed by a physician.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; HLA, human leucocyte antigen; NSAID, non-steroidal anti-inflammatory drug; SIJ, sacroiliac joint; SpA, spondyloarthritis.